introduction to targeted therapies in oncology
TRANSCRIPT
![Page 1: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/1.jpg)
BASICS OF TARGET THERAPY
MOHAMED ABDULLA PROF. OF CLINICAL ONCOLOGYCAIRO UNIVERSITY
NEMROCK – CAIROPFIZER TRAINING COURSESUNDAY: 22/11/2015
![Page 2: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/2.jpg)
SPEAKER DISCLOSURES Member of Advisory Board, Consultant, and Speaker for:Amgen, Astellas, AstraZeneca, Hoffman la Roche, Janssen Cilag, Merck Serono, Novartis, Pfizer
![Page 3: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/3.jpg)
THE NORMAL CELL CYCLE
![Page 4: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/4.jpg)
Class Example Method of Action Cycle Specific
Alkylating agents Cytoxan Effects DNA chemically All
Antimetabolites 5-FUGemzar
Substitutes for normal cell building blocks
S
Anthracyclines Adriamycin DNA damage or inhibit topoisomerase
All
Anti-tumor Antibiotics
Bleomycin DNA damage All
Topoisomerase Inhibitors
Irinotecan Complex DNA and topoisomerase together
SG-2
Vinca Alkaloids Vincristine Binds to tubulin, interferes with mitosis
M
Taxanes TaxolTaxotere
Prevents microtubules from disassociating
M
CLASSES OF CYTOTOXIC THERAPIES
![Page 5: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/5.jpg)
COULD WE DO BETTER?
![Page 6: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/6.jpg)
CHEMOTHERAPY VS TARGETED THERAPYChemotherapy:
• Drugs that effect cells that are doubling• Not very specific• Mostly intravenous, some oral agents• Cytotoxic
Targeted therapy:• Drugs that inhibit a more specific target in cells• Many are oral agents• Mixture of cytostatic and cytotoxic
![Page 7: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/7.jpg)
BIOGRAPHY OF CANCER:Normal Mother Cells Normal Daughter Cells
Abnormal Daughter Cells
Programed Cell Death: APOPTOSIS
RESISTANCE TO APOPTOSIS
Continued Un-opposed Proliferation
Malignant Tumor PROGRESSIONANGIOGENESIS
• Life• Growth• Maintenance
P53
+++Growth Signals
![Page 8: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/8.jpg)
BIOGRAPHY OF CANCER:CANCER = ARREST OF APOPTOSIS + ANGIOGENESIS
P53 GROWTH SIGNALS
Repair of Critical Damage
Growth Factor Receptor Biological Path Nuclear Material Proliferation, Angiogenesis ..
![Page 9: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/9.jpg)
BIOGRAPHY OF CANCER:Growth Factor
Monoclonal Antibody
Normally Existing
++ By The Tumor
TK
1
2
3
![Page 10: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/10.jpg)
Formation of New Blood
Vessels
Physiological
Wound Healing
Placental Implantation
Growth
Pathological
Pre-Eclampsia
Diabetic Retinopathy
Tumors
ANGIOGENESIS:THE WHOLE MARK OF MALIGNANCY:
![Page 11: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/11.jpg)
Proliferation Invasion Metastases
VEGF +
+
TK
+
m-TOR
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 12: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/12.jpg)
New Blood Vessel Proliferation
Release of GFs Receptor Activation
Degradation & Proteolytic Enz.
Disruption of ECM & Wall
Invasion & Migration
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 13: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/13.jpg)
VE
GFR
PI3K AKT
Grb SOS
mTOR
Protein Synthesis
HIF-1@Metabolism
Growth
Angiogenesis
RAS
RAF
Mek
Erk
Cell Cycle Progression & Proliferation
PDG
F
EGFR
1. Avastin [package insert]. South San Francisco, CA: Genentech; 2009. 2. Escudier B et al; TARGET Study Group. N Engl J Med. 2007;356:125-134. 3. Escudier B et al. J Clin Oncol. 2009;27:3312-3318. 4. Nexavar [package insert]. Wayne, NJ: Bayer
Healthcare Pharmaceuticals; 2007.
Bevacizumab
RAD 001 Sorafinib
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 14: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/14.jpg)
Tyrosine Kinase Receptors
VEGFR - 1 VEGFR - 2 VEGFR - 3 NRP - 1 NRP - 2
VEGFs
VEGF - A VEGF - B VEGF - C VEGF - D PlGF
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 15: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/15.jpg)
Hypoxia
HIF
VEGF Gene
VEGF VEGFR on Nearby Vessels VEGFR on Tumor Vessels
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 16: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/16.jpg)
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
Possible Targets for Treatment
Growth Factors
Extracellular Receptor Domain
Tyrosine Kinase Receptor Domain
Critical Protein in Biological Cascade
![Page 17: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/17.jpg)
Blocking VEGF Small Molecule TKI EGFR Inhibitors Soluble VEGF Decoy Receptor
Bevacizumab Sorafinib, Sunitinib, Pazopanib,
Axitinib,Regorafinib
Erlotinib,Gefitinib
Aflibercept
Blocking 100% of VEGF-A Anti-
angiogenic Activity
Wide Range: PDGFR,
C-kit,EGFR,
FGFR Both Anti-angiogenic & Anti-mitogenic Activity
Blocking ERB-1 Receptors Both Anti-angiogenic
and Anti-mitogenic Activity
Blocking VEGF – A and B, PlGF Anti-angiogenic
Activity
IV Bioavailability Oral Bioavailability Oral Bioavailability IV Bioavailability
17 – 21 HLT Short Lived Short Lived Higher Affinity to VEGF-A than other MAB.
ANGIOGENESIS: THE WHOLE MARK OF MALIGNANCY:
![Page 18: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/18.jpg)
BREAKTHROUGHS:1. Trastuzumab in Breast Cancer.2. Rituximab in B-Cell NHL.3. Bevacizumab in Colon and Ovarian Cancer.4. Cetuximab and Panitumumab in Colon Cancer.5. Denosumab in GCTB and Metastatic Bone Disease.6. Imatinib in GIST.7. Everolimus in NET and RCC.8. Sunitinib in RCC.9. Erlotinib and Gefitinib in Non Squamous NSCLC.10. Crizotinib in Non Squamous NSCLC.11. ………
![Page 19: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/19.jpg)
THE ART OF TODAY:• Chemotherapy is still the backbone of most of cancer
treatment protocols.• Targeted Therapies could represent an opened era of
being more personalized and specific in cancer management when added to conventional therapies.
• Some of the TARGETED THERAPIES represent a breakthrough in management (Combo and Sole)
• Others pave the way of pessimistic disease entities.• Still we need to understand much of the molecular events
playing in the back-stage of disease.
![Page 20: Introduction to Targeted Therapies in Oncology](https://reader034.vdocuments.us/reader034/viewer/2022051300/589ff3731a28ab46598b5129/html5/thumbnails/20.jpg)
THANK YOU